Calidi Biotherapeutics (CLDI) Stock Forecast and Price Target (2026)
Last updated July 2026
Short answer
There is no meaningful analyst consensus for Calidi Biotherapeutics (CLDI): too few analysts publish estimates on it for an average target to mean anything. That is normal for smaller and newer companies and says nothing about the business. What is left is the setup, the drivers and the risks below, which you assess yourself rather than starting from someone else's model. Walnut is not an investment adviser.
Why CLDI has no consensus price target
Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with CLDI. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.
A pre-revenue clinical biotech like Calidi cannot be valued on earnings, because there are none; metrics like P/E are not meaningful. Investors who study these companies typically weigh the cash runway against the quarterly burn rate, the timing and probability of upcoming clinical catalysts (such as trial starts, data readouts, and FDA designations), and the dilution required to fund the next stage of development. For Calidi specifically, the very low cash balance, going-concern doubt, reverse split, and heavy warrant overhang mean financing risk and dilution are central to any assessment, and the stock can swing dramatically on capital raises as much as on science.
What could move CLDI from here
In short: the drivers cited most often are Stem-Cell-Shielded Virotherapy Platform, CLD-201 SuperNova and FDA Designations, RTNova Systemic, Redosable Approach. The risk cited most often against it is calidi is a pre-revenue, clinical-stage micro-cap whose value depends almost entirely on early-stage trial outcomes, so a single clinical failure, safety signal, or program delay could sharply reduce the stock.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the CLDI is it a buy page. This page deliberately stops at the numbers.
Investing in Calidi Biotherapeutics with AI
Connect the broker you already use and ask Walnut's AI how CLDI fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the price target for Calidi Biotherapeutics (CLDI)?
+
There is no meaningful consensus price target for CLDI, because too few analysts publish on it. That is common for smaller and newer companies. Where only one or two analysts cover a stock, an "average target" is really one person's model, so we do not print a number that would imply more agreement than exists. Check your broker's research tab for whatever individual coverage exists.
Why does CLDI have no analyst forecast?
+
Sell-side coverage follows trading volume and banking relationships, so small caps, recent listings, and companies outside the major indices often carry little or none. A lack of coverage says nothing about the business itself. It does mean you are doing the analysis yourself rather than starting from someone else's model.
What could move CLDI?
+
The drivers and the risks are laid out on this page and in more depth on the CLDI "is it a buy" page. Without analyst estimates to anchor to, the honest framing is scenarios rather than a number.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a August 2026 data pull of published third-party research, are approximate, and change constantly. Verify current figures with your broker before acting on them.